https://www.biopharmadive.com/news/jpm-22-pfizer-mrna-biogen-price-cell-therapy/616903/
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies...
The healthcare conference's first day brought a trio of mRNA deals from Pfizer, a rare admission from Biogen's CEO and new focus on what's next in cell therapy.
https://www.fiercebiotech.com/biotech/jpm22-day-2
JPM22, Day 2: Sage's double-duty anxiety drug; Dexcom shows off G7 sensor data; Better late than...
Jan 11, 2022 - Welcome to Day 2 of the annual J. P. Morgan Healthcare Conference, gone virtual once more.